Skip to main content

Table 3 Studies measuring circulating HPV DNA in cervical cancer

From: Clinical applications and utility of ctDNA in cervical cancer and its precursor lesions: from screening to predictive biomarker

Markers for

detection

Detection method

Detection rate(%)

Number of patients

Reference

L1/E7

qPCR

25.47

106

12

vh-DNA/E7

qPCR

68.75/81.25

16

26

vh-DNA

Semi-nested PCR

23

21

27

E7/vh-DNA

ddPCR

63/39

94/23

28

L1/E6/E7

PCR enzyme immunoassay

45

94

29

E7

qPCR

18.2

55

30

L1/E7

ddPCR

58.5/55.8

118/138

31

E7

ddPCR

100

19

32

L1

qPCR

14.55

55

48

E7

qPCR

48.48

33

49

E6

nested PCR

24.4

45

50

E6/ E7

qPCR

94.28

140

53

E6/ E7

nested PCR

20

20

56

L1

nested PCR

65

17

57

E7

E7-MPG/ ddPCR

77.63/64.47

76/76

54

HPV DNA

NGS-based CaptHPV

96.77

62

55